In conclusion, SLAMF7 is an attractive target for T-cell immunotherapies due to its high and consistent expression on MM cells, with expression in normal tissues restricted to the hematopoietic system including subsets of T-cells, B cells and NK cells. This evidence concerns the gene SLAMF7 and Miyoshi myopathy.